Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021041878 - PHARMACEUTICAL FORMULATIONS AND DOSAGE REGIMENS FOR MULTI-SPECIFIC BINDING PROTEINS THAT BIND HER2, NKG2D, AND CD16 FOR CANCER TREATMENT

Publication Number WO/2021/041878
Publication Date 04.03.2021
International Application No. PCT/US2020/048500
International Filing Date 28.08.2020
IPC
C07K 16/32 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
32against translation products from oncogenes
C07K 14/82 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
82Translation products from oncogenes
C07K 14/30 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
195from bacteria
30from Mycoplasmatales, e.g. Pleuropneumonia-like organisms (PPLO)
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 2039/507
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
507Comprising a combination of two or more separate antibodies
A61K 2039/54
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
54characterised by the route of administration
A61K 2039/545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
545characterised by the dose, timing or administration schedule
A61K 39/39591
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
39591Stabilisation, fragmentation
A61K 47/183
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
16containing nitrogen, ; e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
183Amino acids, e.g. glycine, EDTA or aspartame
Applicants
  • DRAGONFLY THERAPEUTICS, INC. [US]/[US]
Inventors
  • CHANG, Gregory, P.
  • CHEUNG, Ann, F.
  • CUILLEROT, Jean-Marie
  • GRINBERG, Asya
  • HANEY, William
  • MORGAN, Christopher, Ryan
  • NAILL, Michael, C.
  • WAGTMANN, Nicolai
Agents
  • ASHRAF, Shovon
  • CAI, Yingying
  • BRODOWSKI, Michael, H.
  • ARGENTIERI, Steven, R.
  • BIEKER, Kristina
Priority Data
62/894,04730.08.2019US
62/895,32003.09.2019US
62/916,93518.10.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PHARMACEUTICAL FORMULATIONS AND DOSAGE REGIMENS FOR MULTI-SPECIFIC BINDING PROTEINS THAT BIND HER2, NKG2D, AND CD16 FOR CANCER TREATMENT
(FR) FORMULATIONS PHARMACEUTIQUES ET SCHÉMAS POSOLOGIQUES POUR DES PROTÉINES DE LIAISON MULTI-SPÉCIFIQUES QUI SE LIENT À HER2, NKG2D ET CD16 POUR LE TRAITEMENT DU CANCER
Abstract
(EN)
This disclosure relates to pharmaceutical formulations for multi-specific binding proteins having an epidermal growth factor receptor 2 (ErbB2 or HER2)-binding scFv, an NKG2D-binding Fab, and an antibody Fc domain. Also provided are dosage regimens for such multi-specific binding proteins and pharmaceutical formulations for use in treating cancer, such as locally advanced or metastatic solid tumor.
(FR)
La présente invention concerne des formulations pharmaceutiques pour des protéines de liaison multi-spécifiques ayant un scFv de liaison du récepteur 2 du facteur de croissance épidermique (ErbB2 ou HER2), un Fab de liaison à NKG2D et un domaine Fc d'anticorps. L'invention concerne également des schémas posologiques pour de telles protéines de liaison multi-spécifiques et des formulations pharmaceutiques destinées à être utilisées dans le traitement du cancer, tel qu'une tumeur solide localement avancée ou métastasique.
Latest bibliographic data on file with the International Bureau